About the Company
We do not have any company description for 4D Molecular Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses ... - Nasdaq
4D Molecular Therapeutics, Inc., which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.16 million for the quarter ended June 2022, missing the Zacks Consensus Estimate by 94.60%.
4D Molecular Therapeutics, Inc.: 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week res ...
4D MOLECULAR THERAPEUTICS INC - FinanzNachrichten.de
EMERYVILLE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease ...
4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results ...
EMERYVILLE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted ...
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 ...
EMERYVILLE, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for ...
4D Molecular Therapeutics Announces Closing of Initial Public ... - Nasdaq
--4 D Molecular Therapeutics, Inc., a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today the closing of its initial public ...
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering ...
EMERYVILLE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic ...
4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the ...
No representation is made as to the safety or effectiveness of 4D-150, 4D-310, 4D-710, 4D-125, and 4D-110 for the therapeutic use for which they are being studied. 4D Molecular Therapeutics ...
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase ...
4D Molecular Therapeutics to host a conference call on November 14th, 8:00 am E.T. News provided by 4D Molecular Therapeutics, Inc. Nov 10, 2022, 4:05 PM ET ...
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Intech ...
4D Molecular Therapeutics Stock Down 1.4 % Shares of NASDAQ:FDMT opened at $3.56 on Friday. 4D Molecular Therapeutics, Inc. has a 52-week low of $3.50 and a 52-week high of $34.20. The stock has a ...
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate ...
Similar Companies
Loading the latest forecasts...